Vaccine
Talk

GSK Pentavalent Meningococcal Vaccine Endorsed by ACIP

CDC's Advisory Committee on Immunization Practices (ACIP) endorsed a new GSK pentavalent meningococcal vaccine (MenACWY-CRM/MenB-4C, Penmenvy) for use in people aged ≥10 years when both MenACWY and MenB are indicated.

Safety Profile: The paper is refreshingly transparent about the science, noting: "Serious adverse events possibly related to vaccination were rare and occurred at similar frequencies in pentavalent and control groups."

Health System Impact: On health system impact: "Using pentavalent vaccine as an alternative to concomitant administration of MenACWY and MenB was the most cost-saving of the policy questions considered."

Clinical Significance: For clinicians, researchers, and immunization program managers, this recommendation is less about novelty — and more about implementation efficiency, equity, and real-world feasibility.